Skip to main content

Table 1 Failed, rejected, and reanalysed samples in the comparison of the PyroMark and TheraScreen K-RAS assays

From: KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice

DNA #

PyroMark

TheraScreen

Comments

21

ND

ND

Pyro: Failed, repeated twice. DxS: Rejected, control Ct > 35

25

WT

ND

Pyro: Check, triplicate = wt. DxS: Rejected, control Ct > 35

30

WT

ND

Pyro: Check, triplicate = wt. DxS: Rejected, control Ct > 35

37

ND

ND

Pyro: Check, triplicate = inconclusive. DxS: Rejected, control Ct > 35

54

WT

12 GTT

Pyro: Triplicate = wt. DxS: 12 GTT mutation

61

WT

ND

DxS: Rejected, control Ct > 35

64

ND

ND

Pyro: Failed. DxS: Rejected, control Ct > 35

66

12 GAT

ND

Pyro: Check, triplicate = 12 GAT mutation. DxS: Rejected, control Ct > 35

67

ND

ND

Pyro: Failed, repeated in triplicate. DxS: Rejected, control Ct > 35

89

ND

ND

Pyro: Failed. DxS: Rejected, control Ct > 35

93

ND

WT

Pyro: Check, triplicate = inconclusive. DxS: triplicate = wt

100

12 GTT

12 GTT

Pyro: Low mutation signal, triplicate = 12 GTT mutation. DxS: 12 GTT mutation

  1. Summary of the mutational status of samples with "check", "failed" (PyroMark) or "rejected" (TheraScreen, DxS) status. ND = mutation status could not be determined.